Trump administration reveals 'most favored nation' drug price country targets
The Department of Health and Human Services provided the first details for how it plans to tie US drug prices to rates paid in similarly developed countries as part of President Donald Trump’s most...
View ArticleSV Health’s $269M dementia fund; Schrödinger lays off 7% of staff
Plus, news about Beckley Psytech, Regenxbio, Blueprint Medicines, VantAI, NovelMed and Bayer: 💰 SV Health closes second dementia fund: The London-based biotech investment firm closed its second...
View ArticleTourmaline Bio's heart drug cuts inflammation as it seeks to compete with...
Tourmaline Bio's experimental drug for atherosclerotic heart disease reduced markers of inflammation in the blood in a mid-stage study. The company must now show the drug cuts key events such as heart...
View ArticleFuture Covid vaccine approvals may narrow to older adults, high-risk people
FDA chief Marty Makary and new CBER Director Vinay Prasad said that future Covid-19 vaccine approvals will focus on adults over 65 and high-risk people 6 months to 64 years old, aligning US policy with...
View ArticleRFK Jr. spars with senators over HHS budget and research cuts
Senate Democrats grilled HHS Secretary Robert F. Kennedy Jr. on Tuesday over gaps in his budget and funding cuts that have halted or eliminated key clinical research. For the most part, Kennedy pleaded...
View ArticleCRISPR Therapeutics partners with siRNA company, showing that gene editing...
The gene editing company CRISPR Therapeutics struck a deal worth $95 million upfront with China-based biotech Sirius Therapeutics to jointly develop its experimental gene-silencing siRNA drug for blood...
View ArticleUpdated: FDA adcomm splits votes on Genentech and J&J cancer drugs
The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US patient population for a Columvi label expansion. In the afternoon session,...
View ArticleVinay Prasad makes first major imprint on FDA with new vaccine policy
Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for approving future Covid-19 vaccines that he feels will counteract existing “dogma.”...
View ArticleUK biotech Juvenescence targets $150M+ for 'healthy lifespan' drug candidates
The "healthy lifespan" space is attracting more dollars. Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic. The drug development startup,...
View ArticleReproductive health biotech ReproNovo closes $65M Series A
A Swiss biotech has secured $65 million to launch a trio of mid-stage trials for two reproductive health drugs. ReproNovo announced the close of its Series A round on Wednesday. CEO Jean Marie Duvall...
View ArticleAltos Labs buys anti-aging startup Dorian Therapeutics
Altos Labs, the massive but still relatively secretive $3 billion biotech, has forged a small acquisition of a startup seeking to reverse aging. Altos, led by industry stalwarts Hal Barron and Hans ...
View ArticleHow PureTech’s lung fibrosis drug stacks up against the competition
PureTech Health’s tweaked form of Roche’s lung fibrosis drug Esbriet slowed lung function decline by a greater degree than Esbriet itself, with comparable safety, the company said Tuesday. On a cross ...
View ArticleGenentech expands partnership with molecular glue biotech Orionis
Roche’s subsidiary Genentech is signing a second deal with Orionis Biosciences to expand its search through the world of protein interactions in hopes of developing new cancer drugs. The two companies...
View ArticleResearchers reveal mixed results from vaccine for cocaine addiction
Scientists from Weill Cornell Medicine in New York have announced the results from a long-awaited but small study of a vaccine designed to soak up cocaine molecules and help people addicted to the...
View ArticleModerna pulls application for Covid-flu shot; Another IPO in Hong Kong
Plus, news about Genfit, Ipsen, Accropeutics, Merck KGaA, Alumis and Acelyrin: Moderna pulls BLA for its Covid-flu shot: The company suggested on its most recent earnings call earlier this month that...
View ArticleBiotech downturn exposes startups to big lease liabilities
For some biotechs, the office is a place where scientists gather and pipelines advance. For others, it’s a boat anchor dragging them to the bottom of the sea. Four years into the biotech downturn, some...
View ArticleBioNTech invests £1B in growing UK footprint under expanded pact with government
BioNTech is spending up to £1 billion over the next ten years to boost its R&D activities in the UK as part of an enhanced agreement with the UK government. The government is supplying BioNTech ...
View ArticleFDA adcomm narrowly votes against UroGen’s bladder cancer drug
The FDA's Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen Pharma's mitomycin as an option for low-grade intermediate-risk non-muscle invasive bladder cancer. Panelists and...
View ArticleEikon Therapeutics cuts staff following $351M Series D
Eikon Therapeutics is laying off staff for the second time in 19 months, responding to “changes in external circumstances” that have created “financial challenges.” That was the rationale relayed to...
View Article